<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Granulocyte cytotoxic activity in sera from over 257 patients was shown to be distinct from <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>-A lymphocytoxic activity </plain></SENT>
<SENT sid="1" pm="."><plain>Granulocyte cytotoxins occur in approximately 25 per cent of sera from patients having <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 45 per cent with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, 22 per cent with <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> on hemodialysis, and 19 per cent of pregnant women </plain></SENT>
<SENT sid="2" pm="."><plain>By testing sera on the same panel of cells, the granulocyte cytotoxic activity was shown not to be associated with granulocyte agglutination activity or lymphocytotoxic acitivty </plain></SENT>
<SENT sid="3" pm="."><plain>It is likely that granulocyte cytotoxins and granulocyte agglutinins will be useful in transfusion and bone marrow transplantation as a separate tool from the more widely used lymphocyte cytotoxicity reaction </plain></SENT>
</text></document>